Epidemiology of cytokines: The women on the move through activity and nutrition (WOMAN) study

American Journal of Epidemiology

Volumn 168, Issue 4, 2008, Pages 443-453

  Wong, Eric ^a   Freiberg, Matthew ^a,b   Tracy, Russell ^c   Kuller, Lewis ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

Cytokines; Hormones; Inflammation; Obesity; Weight loss; Women

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ACTIVITY PATTERN; CARDIOVASCULAR DISEASE; ELDERLY POPULATION; EPIDEMIOLOGY; HORMONE; NUTRITION; OBESITY; PROTEIN; RISK FACTOR; TUMOR; WEIGHT; WOMENS HEALTH;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; CHEMOKINE CXCL10; CYTOKINES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-1ALPHA; INTERLEUKIN-4; INTERLEUKIN-6; INTERLEUKIN-8; LINEAR MODELS; MIDDLE AGED; OBESITY; PENNSYLVANIA; POSTMENOPAUSE; PROSPECTIVE STUDIES; PROTEOMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-1; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS; WOMEN'S HEALTH;

NORTH AMERICA; PENNSYLVANIA; UNITED STATES;

EID: 49449102755     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn132     Document Type: Article

References (71)

1. Tracy RP. Inflammation in cardiovascular disease. Circulation 1998;97:2000-2.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
4. Hafler DA, ed. Cytokines and cytokine therapies. (Special issue). Nat Rev Immunol 2007;7:423-65. (http://www.nature.com/nri/focus/cytokines/index.html).
5. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;10:299-304.
6. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 2006;114:1185-92.
7. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006;354:1166-76.
8. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19.
9. Kuller LH, Kriska AM, Kinzel LS, et al. The clinical trial of Women On the Move through Activity and Nutrition (WOMAN) Study. Contemp Clin Trials 2007;28:370-81.
10. Fraser CG, ed. Biological variation: from principles to practice. Washington, DC: AACC Press, 2001.
11. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
12. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
15. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
16. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
17. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002;966:143-57.
18. Mueck AO, Seege H. Estrogens acting as cardiovascular agents: direct vascular actions. Curr Med Chem Cardiovasc Hematol Agents 2004;2:35-42.
19. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002;55:714-26.
20. Koh KK, Yoon BK. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22-30.
21. Hu P, Greendale GA, Palla SL, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The Postmenopausal Estrogen Progestin Intervention (PEPI) Trial. Atherosclerosis 2006;185:347-52.
22. Koh KK, Schenke WH, Waclawiw M, et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002;105:1531-3.
23. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22.
24. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-25.
25. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of estrogen and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-22.
26. Cushman M, Meilhan EN, Psaty BM, et al. Hormone replacement therapy, inflammation and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-9.
27. Walsh BW, Cox DA, Sashegyi A, et al. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-8.
28. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:3165-9.
29. Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestin combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-6.
30. Stork S, Baumann K, von Schacky C, et al. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res 2002;53:642-9.
31. Koh KK, Son JW, Jin DK, et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int J Cardiol 2001;81:43-50.
32. Koh KK, Ahn JY, Jin DK, et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol 2002;22:1459-64.
33. Festa A, D'Agostino R Jr, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-15.
34. Barinas-Mitchell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001;153:1094-101.
35. Ohman MK, Shen Y, Obima CI, et al. Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117:798-805.
36. Pou KM, Massaro JM, Hoffman U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 2007;116:1234-41.
37. Musaad S, Haynes EN. Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev 2007;29:98-114.
38. Kuller LH, Kinzel LS, Pettee KK, et al. Lifestyle intervention and coronary heart disease risk factor changes over 18 months in postmenopausal women: the Women On the Move through Activity and Nutrition (WOMAN Study) clinical trial. J Womens Health (Larchmt) 2006;15:962-74.
39. Gallicchio L, Chang H, Christo DK, et al. Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland. Am J Epidemiol 2008;167:807-13.
40. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
41. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
42. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:2066-71.
43. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: The NHLBI Family Heart Study. Atherosclerosis 2001;154:681-9.
44. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:67-77.
45. Lange LA, Carlson CS, Hindorff LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006;296:2703-11.
46. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol 2008;167:313-20.
47. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002;34:204-9.
48. Smith AJP, Keen LJ, Billingham MJ, et al. Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: association with knee osteoarthritis. Genes Immun 2004;5:451-60.
49. Bennet AM, van Maarle MC, Hallqvist J, et al. Association of TNF-α serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis 2006;187:408-14.
50. Huber SA, Sakkinen P, Conze D, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999;19:2364-7.
51. Schieffer B, Selle T, Hilfiker A, et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004;110:3493-500.
52. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor -/- mice. Arterioscler Thromb Vasc Biol 2002;22:456-61.
53. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
54. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999;398:718-23.
55. Lee YW, Kühn H, Hennig B, et al. IL-4 induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001;33:83-94.
56. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-62.
57. Kanters E, Pasparakis M, Gijbels MJ, et al. Inhibition of NFkappaB activation in macrophages increase atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;112:1176-85.
58. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
59. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action and insulin secretion. Obes Res 2001;9:414-17.
60. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 2006;17:365-71.
61. Piche M-E, Lemieux S, Weisnagel SJ, et al. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005;96:92-7.
62. Hung J, McQuillan BM, Chapman CML, et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005;25:1268-73.
63. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6 dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-6.
64. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
65. Rothenbacher D, Müller-Scholze S, Herder C, et al. Differential expression of chemokines, risk of stable coronary heart disease and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006;26:194-9.
66. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/ KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006;26:2745-51.
67. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: The Health Aging and Body Composition Study. J Bone Miner Res 2007;22:1088-95.
68. Roy HK, Khandekar JD. Biomarkers for the early detection of cancer: an inflammatory concept. Arch Intern Med 2007;167:1822-4.
69. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
70. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
71. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord 2003;27(suppl 3):S29-34.